Assessment of Cardiac Function and Myocardial Morphology Using Small Animal Look-locker Inversion Recovery (SALLI) MRI in Rats

Small animal magnetic resonance  imaging is an important tool to study cardiac function and changes in myocardial  tissue. The high heart rates of small ...

German Heart Institute Berlin

To correlate intestinal contrast enhancement and wall thickening with the degree of inflammation in an experimental model of inflammatory bowel disease. MATERIALS and

Magnetic resonance imaging of inflammatory bowel disease: evaluation in a rabbit model.

&Agrave; l&#39;am&eacute;lioration du contraste intestinale et &eacute;paississement de la paroi en corr&eacute;lation avec le degr&eacute; d&#39;inflammation dans un mod&egrave;le exp&eacute;rimental de maladie inflammatoire de l&#39;intestin. MAT&Eacute;RIAUX et

Imagerie par r&eacute;sonance magn&eacute;tique des maladies inflammatoires de l&#39;intestin : &eacute;valuation dans un mod&egrave;le de lapin.

Per correlare intestinale contrast enhancement e ispessimento della parete con il grado di infiammazione in un modello sperimentale di malattia infiammatoria intestinale. MATERIALI e

Risonanza magnetica delle malattie infiammatorie intestinali: valutazione in un modello di coniglio.

To evaluate the ability of ultrahigh-field magnetic resonance imaging (MRI) to accurately depict the composition of the human arterial vessel wall ex vivo and to detect early atherosclerotic lesion formation in comparison to histology.

Experimental evaluation of the detectability of submillimeter atherosclerotic lesions in ex vivo human iliac arteries with ultrahigh-field (7.0 T) magnetic resonance imaging.

D&#39;&eacute;valuer la capacit&eacute; des ultra-champ de r&eacute;sonance magn&eacute;tique (IRM) pour d&eacute;crire avec pr&eacute;cision la composition de la paroi des vaisseaux art&eacute;riels humaine ex vivo et pour d&eacute;tecter la formation de la l&eacute;sion ath&eacute;roscl&eacute;reuse pr&eacute;coce en comparaison de l&#39;histologie.

&Eacute;valuation exp&eacute;rimentale de la d&eacute;tectabilit&eacute; des l&eacute;sions ath&eacute;roscl&eacute;reuses de Planck en ex vivo des art&egrave;res iliaques humaines avec ultra-champ (7,0 T) de r&eacute;sonance magn&eacute;tique.

Per valutare la capacit&agrave; di ultraelevato-campo risonanza magnetica (MRI) per rappresentare accuratamente la composizione della parete del vaso arterioso umano ex vivo e per rilevare la formazione di lesione aterosclerotica precoce rispetto a istologia.

Valutazione sperimentale di individuabilit&agrave; delle lesioni aterosclerotiche submillimeter in ex vivo umano arterie iliache con ultraelevato-campo (7,0 T) risonanza magnetica.

It has been shown that ED-B fibronectin (ED-B) is a potential target for plaque imaging. The aim of this study was to test a novel modified single chain anti-ED-B antibody (scFv) conjugated for near infrared fluorescence imaging (NIRF) with tetrasulfonated carbocyanine-maleimide (TSC-scFv) and to examine the association of ED-B with the presence of macrophages in a murine model of atherosclerosis. Expression of ED-B was observed in plaque areas in apolipoprotein E-deficient (apoE(-/-)) mice which increased with age and plaque load. Robust imaging was possible after explantation of the aorta and demonstrated a strong NIRF signal intensity in focal aortic and brachiocephalic plaque lesions, whereas no signals were found in undiseased areas. Plaque lesion ED-B was expressed by smooth muscle cell and was closely associated to macrophage infiltrates. Although not expressed by the same cell type, there was a significant correlation (p<0.01) between ED-B and macrophage immunoreactivity. In vitro human coronary and mouse smooth muscle cells significantly increased ED-B expression after angiotensin II and TNF-alpha treatment. This study demonstrates that plaque NIRF imaging is feasible with a novel single chain antibody and that ED-B expression is closely associated with inflammation in experimental atherosclerosis.

ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions.

Il a &eacute;t&eacute; d&eacute;montr&eacute; que la fibronectine ED-B (ED-B) est une cible potentielle pour l&#39;imagerie de la plaque. Le but de cette &eacute;tude &eacute;tait de tester un roman modifi&eacute; de cha&icirc;ne unique anti-ED-B anticorps (scFv) pour pr&egrave;s de fluorescence infrarouge d&#39;imagerie (NIRF) avec tetrasulfonated carbocyanine-mal&eacute;imide (TSC-scFv) et &agrave; examiner les liens de l&#39;ED-B avec la pr&eacute;sence de macrophages dans un mod&egrave;le murin d&#39;ath&eacute;roscl&eacute;rose. Expression de ED-B a &eacute;t&eacute; observ&eacute;e dans les zones de la plaque en apolipoprot&eacute;ine E-deficient (souris apoE(-/-)) qui augmentent avec l&#39;&acirc;ge et la plaque de charge. Imagerie robuste a &eacute;t&eacute; possible apr&egrave;s explantation de l&#39;aorte et d&eacute;montr&eacute; une forte NIRF signal d&#39;intensit&eacute; dans les l&eacute;sions focales plaque aortique et brachioc&eacute;phalique, consid&eacute;rant qu&#39;aucun signal ne trouv&eacute;es dans les zones undiseased. Plaque l&eacute;sion ED-B a &eacute;t&eacute; exprim&eacute;e par la cellule musculaire lisse et a &eacute;t&eacute; &eacute;troitement associ&eacute;e &agrave; des infiltrats de macrophages. Bien que non exprim&eacute; par le m&ecirc;me type de cellule, il y avait une corr&eacute;lation significative (p &lt; 0,01) entre l&#39;immunor&eacute;activit&eacute; ED-B et les macrophages. Expression de ED-B significativement accrue apr&egrave;s l&#39;angiotensine II et traitement de TNF-alpha des cellules in vitro humain muscle lisse coronaire et de la souris. Cette &eacute;tude d&eacute;montre que l&#39;imagerie NIRF plaque est faisable avec un anticorps cha&icirc;ne unique roman et qu&#39;expression ED-B est &eacute;troitement li&eacute;e &agrave; l&#39;inflammation dans l&#39;ath&eacute;roscl&eacute;rose exp&eacute;rimentale.

ED-B la fibronectine (ED-B) peut &ecirc;tre cibl&eacute;e &agrave; l&#39;aide d&#39;un conjugu&eacute; d&#39;anticorps cha&icirc;ne unique roman et est associ&eacute;e &agrave; l&#39;accumulation des macrophages dans les l&eacute;sions ath&eacute;roscl&eacute;rotiques.

&Egrave; stato dimostrato che la fibronectina ED-B (ED-B) &egrave; un potenziale bersaglio per l&#39;imaging di placca. Lo scopo di questo studio era di testare un romanzo modificato dell&#39;anticorpo anti-ED-B singola catena (scFv) coniugato per vicino a fluorescenza a raggi infrarossi imaging (NIRF) con tetrasulfonated carbocyanine-con (TSC-scFv) e di esaminare l&#39;associazione di ED-B con la presenza di macrofagi in un modello murino di aterosclerosi. Espressione di B ED &egrave; stato osservato nelle zone di placca in apolipoproteina E-carenti (apoE(-/-)) topi che aumenta con l&#39;et&agrave; e la placca di carico. Imaging robusto era possibile dopo l&#39;espianto dell&#39;aorta e hanno dimostrato un forte NIRF segnale di intensit&agrave; nelle lesioni focali placca aortica e brachicefala, mentre nessun segnale sono stato trovato nelle zone undiseased. Lesione placca B ED &egrave; stata espressa da cellule muscolari lisce e fu strettamente associata a macrofagi infiltrati. Anche se non espresse dallo stesso tipo di cella, c&#39;era una correlazione significativa (p &lt; 0,01) tra immunoreattivit&agrave; ED-B e dei macrofagi. In vitro umano coronaria e mouse muscolo liscio cellule significativamente aumentata espressione ED-B dopo trattamento di TNF-alfa e angiotensina II. Questo studio dimostra che la placca NIRF imaging &egrave; fattibile con un anticorpo romanzo catena singola e che espressione B ED &egrave; strettamente associato con l&#39;infiammazione in aterosclerosi sperimentale.

ED-B fibronectina (ED-B) pu&ograve; essere mirata utilizzando un anticorpo coniugato con catena singola romanzo ed &egrave; associata con accumulo di macrofagi nelle lesioni aterosclerotiche.

Gehirnentz&uuml;ndung ist ein Markenzeichen des Striches, wo es in Gewebesch&auml;den sowie Reparatur verwickelt war. Imaging-Technologien, die speziell diese Prozesse visualisieren sind sehr w&uuml;nschenswert. In dieser Studie haben wir untersucht, ob der entz&uuml;ndliche Rezeptor CD40 invasiv werden kann und speziell bei M&auml;usen nach zerebraler Isch&auml;mie mit einen fluoreszierenden monoklonalen Antik&ouml;rper, die wir mit der Nah-Infrarot-Fluoreszenz-Farbstoff Cy5.5 (Cy5.5-CD40MAb) beschriftet visualisiert.

In-vivo Bildgebung des entz&uuml;ndlichen Rezeptors CD40 nach zerebraler Isch&auml;mie mit einen fluoreszierenden Antik&ouml;rper.

Infiammazione del cervello &egrave; una caratteristica della corsa, dove &egrave; stato implicato nel danno tissutale, cos&igrave; come in riparazione. Tecnologie di imaging che specificamente visualizzare questi processi sono altamente desiderabile. In questo studio, abbiamo esplorato se infiammatorio recettore CD40 pu&ograve; essere invasivo e specificamente visualizzati nei topi dopo ischemia cerebrale utilizzando un anticorpo monoclonale fluorescente, che abbiamo contrassegnati con la tintura vicino infrarosso fluorescenza incubiamo (incubiamo-CD40MAb).

In vivo imaging del recettore CD40 infiammatorio dopo ischemia cerebrale usando un anticorpo fluorescente.

&#x8111;&#x90E8;&#x708E;&#x75C7;&#x7684;&#x63CF;&#x8FB9;&#xFF0C;&#x7279;&#x70B9;&#x662F;&#xFF0C;&#x5B83;&#x4E00;&#x76F4;&#x5728;&#x53C2;&#x4E0E;&#x7EC4;&#x7EC7;&#x635F;&#x4F24;&#x4EE5;&#x53CA;&#x4FEE;&#x590D;&#x3002;&#x5177;&#x4F53;&#x76F4;&#x89C2;&#x663E;&#x793A;&#x8FD9;&#x4E9B;&#x8FDB;&#x7A0B;&#x7684;&#x6210;&#x50CF;&#x6280;&#x672F;&#xFF0C;&#x662F;&#x975E;&#x5E38;&#x7406;&#x60F3;&#x3002;&#x5728;&#x6B64;&#x7814;&#x7A76;&#x4E2D;&#xFF0C;&#x6211;&#x4EEC;&#x63A2;&#x8BA8;&#x662F;&#x5426;&#x708E;&#x75C7;&#x7684;&#x53D7;&#x4F53; CD40 &#x53EF;&#x4EE5;&#x901A;&#x8FC7;&#x4E0E;&#x4F7F;&#x7528;&#x8367;&#x5149;&#x7684;&#x5355;&#x514B;&#x9686;&#x6297;&#x4F53;&#xFF0C;&#x6211;&#x4EEC;&#x7528; Cy5.5 (Cy5.5-CD40MAb) &#x7684;&#x8FD1;&#x7EA2;&#x5916;&#x8367;&#x5149;&#x67D3;&#x6599;&#x6807;&#x8BB0;&#x7684;&#x7F3A;&#x8840;&#x6027;&#x8111;&#x635F;&#x4F24;&#x540E;&#x5C0F;&#x9F20;&#x7684;&#x4E13;&#x95E8;&#x53EF;&#x89C6;&#x5316;&#x3002;

&#x4F7F;&#x7528;&#x8367;&#x5149;&#x6297;&#x4F53;&#x7684;&#x8111;&#x7F3A;&#x8840;&#x540E;&#x708E;&#x75C7;&#x7684;&#x53D7;&#x4F53; CD40 &#x7684;&#x6D3B;&#x4F53;&#x6210;&#x50CF;&#x3002;

Brain inflammation is a hallmark of stroke, where it has been implicated in tissue damage as well as in repair. Imaging technologies that specifically visualize these processes are highly desirable. In this study, we explored whether the inflammatory receptor CD40 can be noninvasively and specifically visualized in mice after cerebral ischemia using a fluorescent monoclonal antibody, which we labeled with the near-infrared fluorescence dye Cy5.5 (Cy5.5-CD40MAb).

In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody.

Inflammation du cerveau est une caract&eacute;ristique des accidents vasculaires c&eacute;r&eacute;braux, o&ugrave; il a &eacute;t&eacute; impliqu&eacute; dans des l&eacute;sions tissulaires, ainsi qu&#39;en r&eacute;paration. Technologies de l&#39;imagerie que de visualiser plus pr&eacute;cis&eacute;ment ces processus sont fortement souhaitables. Dans cette &eacute;tude, nous explor&eacute; si le r&eacute;cepteur inflammatoire CD40 peut &ecirc;tre une fa&ccedil;on non envahissante et visualis&eacute; sp&eacute;cifiquement chez les souris apr&egrave;s une isch&eacute;mie c&eacute;r&eacute;brale utilisant un anticorps monoclonal fluorescent, qui nous marqu&eacute;s par l&#39;agent de la fluorescence du proche infrarouge Cy5. 5 (Cy5. 5-CD40MAb).

Imagerie in vivo du r&eacute;cepteur inflammatoire CD40 apr&egrave;s isch&eacute;mie c&eacute;r&eacute;brale, &agrave; l&#39;aide d&#39;un anticorps fluorescent.

&#x8133;&#x306E;&#x708E;&#x75C7;&#x30B9;&#x30C8;&#x30ED;&#x30FC;&#x30AF;&#x306E;&#x7279;&#x5FB4;&#x306F;&#x3001;&#x305D;&#x308C;&#x306F;&#x4FEE;&#x7406;&#x306E;&#x3088;&#x3046;&#x306B;&#x3001;&#x7D44;&#x7E54;&#x640D;&#x50B7;&#x306B;&#x95A2;&#x4E0E;&#x3057;&#x3066;&#x3044;&#x308B;&#x3067;&#x3059;&#x3002;&#x5177;&#x4F53;&#x7684;&#x306B;&#x3053;&#x308C;&#x3089;&#x306E;&#x30D7;&#x30ED;&#x30BB;&#x30B9;&#x3092;&#x53EF;&#x8996;&#x5316;&#x3059;&#x308B;&#x30A4;&#x30E1;&#x30FC;&#x30B8;&#x30F3;&#x30B0;&#x6280;&#x8853;&#x306F;&#x3001;&#x975E;&#x5E38;&#x306B;&#x671B;&#x307E;&#x3057;&#x3044;&#x3067;&#x3059;&#x3002;&#x672C;&#x7814;&#x7A76;&#x306F;, &#x708E;&#x75C7;&#x6027;&#x53D7;&#x5BB9;&#x4F53; CD40 &#x8972;&#x3059;&#x308B;&#x3053;&#x3068;&#x304C;&#x3067;&#x304D;&#x308B;&#x304B;&#x3069;&#x3046;&#x304B;&#x3092;&#x691C;&#x8A0E;&#x3057;&#x3001;&#x5177;&#x4F53;&#x7684;&#x306B;&#x30DE;&#x30A6;&#x30B9;&#x3067;&#x6211;&#x3005; &#x306F;&#x8FD1;&#x8D64;&#x5916;&#x86CD;&#x5149;&#x8272;&#x7D20; Cy5.5 (Cy5.5 CD40MAb) &#x3068;&#x3044;&#x3046;&#x30E9;&#x30D9;&#x30EB;&#x3092;&#x86CD;&#x5149;&#x30E2;&#x30CE;&#x30AF;&#x30ED;&#x30FC;&#x30CA;&#x30EB;&#x6297;&#x4F53;&#x3092;&#x7528;&#x3044;&#x305F;&#x8133;&#x865A;&#x8840;&#x5F8C;&#x8996;&#x899A;&#x5316;&#x3002;

&#x8133;&#x865A;&#x8840;&#x5F8C; CD40 &#x708E;&#x75C7;&#x6027;&#x53D7;&#x5BB9;&#x4F53;&#x306E; in vivo &#x30A4;&#x30E1;&#x30FC;&#x30B8;&#x30F3;&#x30B0;&#x306B;&#x304A;&#x3051;&#x308B;&#x86CD;&#x5149;&#x6297;&#x4F53;&#x3092;&#x4F7F;&#x7528;&#x3057;&#x3066;&#x304F;&#x3060;&#x3055;&#x3044;&#x3002;

&#xB1CC; &#xC5FC;&#xC99D;&#xC740; &#xC120;&#xC758; &#xAC01; &#xC778; &#xC870;&#xC9C1; &#xC190;&#xC0C1; &#xBFD0;&#xB9CC; &#xC544;&#xB2C8;&#xB77C; &#xC218;&#xB9AC;&#xB85C; &#xC5F0;&#xB8E8; &#xB418;&#xC5B4; &#xC788;&#xB2E4;. &#xAD6C;&#xCCB4;&#xC801;&#xC73C;&#xB85C; &#xC774;&#xB7EC;&#xD55C; &#xD504;&#xB85C;&#xC138;&#xC2A4;&#xB97C; &#xC2DC;&#xAC01;&#xD654; &#xD558;&#xB294; &#xC774;&#xBBF8;&#xC9D5; &#xAE30;&#xC220;&#xC744; &#xB9E4;&#xC6B0; &#xBC14;&#xB78C;&#xC9C1;&#xD55C; &#xC788;&#xC2B5;&#xB2C8;&#xB2E4;. &#xC774; &#xC5F0;&#xAD6C;&#xC5D0;&#xC11C; &#xC6B0;&#xB9AC;&#xAC00; &#xC5FC;&#xC99D; &#xC131; &#xC218;&#xC6A9; &#xCCB4; CD40 noninvasively &#xB420; &#xC218; &#xC788;&#xB294;&#xC9C0; &#xC5EC;&#xBD80;&#xB97C; &#xD0D0;&#xC0C9; &#xD558; &#xACE0; &#xAD6C;&#xCCB4;&#xC801;&#xC73C;&#xB85C; &#xC6B0;&#xB9AC; &#xADFC; &#xC801;&#xC678;&#xC120; &#xD615;&#xAD11; &#xC5FC;&#xB8CC; Cy5.5 (Cy5.5-CD40MAb)&#xC640; &#xD568;&#xAED8; &#xD45C;&#xC2DC; &#xB41C; &#xD615;&#xAD11;&#xC758; &#xB2E8;&#xC77C; &#xD074;&#xB860; &#xD56D; &#xCCB4;&#xB97C; &#xC0AC;&#xC6A9; &#xD558; &#xC5EC; &#xB300;&#xB1CC; &#xAD6D; &#xC18C; &#xBE48; &#xD608; &#xD6C4; &#xC0DD;&#xC950;&#xC5D0;&#xC11C; &#xC2DC;&#xAC01;.

&#xD615;&#xAD11; &#xD56D; &#xCCB4;&#xB97C; &#xC0AC;&#xC6A9; &#xD558; &#xC5EC; &#xB300;&#xB1CC; &#xAD6D; &#xC18C; &#xBE48; &#xD608; &#xD6C4; CD40 &#xC5FC;&#xC99D; &#xC131; &#xC218;&#xC6A9; &#xCCB4;&#xC758; in vivo &#xC601;&#xC0C1;.

Inflamaci&oacute;n del cerebro es un sello de tiempos, donde se ha implicado en da&ntilde;o de tejido, as&iacute; como en reparaci&oacute;n. Tecnolog&iacute;as de proyecci&oacute;n de imagen que espec&iacute;ficamente visualizaci&oacute;n estos procesos son altamente deseables. En este estudio, hemos explorado si el receptor inflamatorio CD40 puede ser de forma no invasiva y espec&iacute;ficamente visualizados en ratones tras la isquemia cerebral usando un anticuerpo monoclonales fluorescente, que etiquetamos con el colorante de la fluorescencia del infrarrojo cercano Cy5.5 (Cy5.5-CD40MAb).

Imagen in vivo del receptor CD40 inflamatorio tras la isquemia cerebral usando un anticuerpo fluorescente.

Ezetimibe (EZE), an inhibitor of cholesterol absorption, reduces atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. The matrix protein ED-B fibronectin (ED-B) is upregulated in atherosclerotic lesions. Using a novel conjugate for near-infrared fluorescence (NIRF) imaging targeting ED-B, we studied the effect of EZE on plaque lesion formation in apoE(-/-) mice. ApoE(-/-) mice received EZE (5 mug/kg/d) or chow up to the age of 4, 6, and 8 months. NIRF imaging of aortic lesions was performed 24 hours after intravenous application ex vivo and in vivo. Plaque lesion formation was analyzed by histology and immunohistochemistry. Aortic lesion formation detected by Sudan staining and NIRF imaging was significantly reduced at 6 and 8 months (p < .001). Plaque areas determined by NIRF imaging significantly correlated with Sudan staining (p < .001). EZE treatment resulted in a significant reduction in plaque macrophage and ED-B immunoreactivity (both p < .05) in brachiocephalic lesions. There was a significant reduction in plaque size in brachiocephalic arteries in 8-month-old mice treated with EZE compared with mice during short-term treatment (p < .05), indicating EZE plaque regression. Targeted NIRF imaging showed a correlation to histologic lesion extension during therapeutical intervention in experimental atherosclerosis.

Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis.

Ezetimibe (EZE), un inhibiteur de l&#39;absorption du cholest&eacute;rol, r&eacute;duit l&#39;ath&eacute;roscl&eacute;rose en apolipoprot&eacute;ine E-deficient (apoE(-/-)) souris. La matrice prot&eacute;ique ED-B la fibronectine (ED-B) est augment&eacute;e dans les l&eacute;sions ath&eacute;roscl&eacute;rotiques. &Agrave; l&#39;aide d&#39;un roman conjugu&eacute; pour le proche-infrarouge fluorescence (NIRF) imagerie ciblage ED-B, nous avons &eacute;tudi&eacute; l&#39;effet d&#39;EZE sur la formation de l&eacute;sions chez la souris apoE(-/-) plaque. ApoE(-/-) souris ont re&ccedil;u EZE (5 tasse/kg/j) ou chow jusqu&#39;&agrave; l&#39;&acirc;ge de 4, 6 et 8 mois. L&#39;imagerie des l&eacute;sions aortiques NIRF a &eacute;t&eacute; r&eacute;alis&eacute;e 24 heures apr&egrave;s l&#39;application par voie intraveineuse, ex vivo et in vivo. La formation de l&eacute;sions plaque a &eacute;t&eacute; analys&eacute;e par l&#39;histologie et l&#39;immunohistochimie. La formation de l&eacute;sions aortiques d&eacute;tect&eacute;e par la coloration du Soudan et de l&#39;imagerie NIRF a &eacute;t&eacute; significativement r&eacute;duite &agrave; 6 et 8 mois (p &lt;. 001. Domaines plaque par imagerie NIRF significativement corr&eacute;l&eacute;e avec la coloration de Soudan (p &lt;. 001. Traitement d&#39;EZE a entra&icirc;n&eacute; une r&eacute;duction significative dans les macrophages de la plaque et l&#39;immunor&eacute;activit&eacute; de l&#39;ED-B (les deux p &lt;.05) l&eacute;sions brachioc&eacute;phalique. Il y avait une r&eacute;duction significative de la taille de la plaque dans les art&egrave;res brachioc&eacute;phalique dans 8 mois souris trait&eacute;es avec EZE par rapport aux souris pendant le traitement &agrave; court terme (p &lt;.05), indiquant la r&eacute;gression plaque EZE. L&#39;imagerie NIRF cibl&eacute;e ont montr&eacute; une corr&eacute;lation &agrave; l&#39;extension de la l&eacute;sion histologique pendant l&#39;intervention th&eacute;rapeutique dans l&#39;ath&eacute;roscl&eacute;rose exp&eacute;rimentale.

Surveillance intervention th&eacute;rapeutique avec l&#39;aide de l&#39;&eacute;z&eacute;timibe cibl&eacute;es imagerie de fluorescence proche infrarouge dans l&#39;ath&eacute;roscl&eacute;rose exp&eacute;rimentale.

Ezetimibe (EZE), un inibitore dell&#39;assorbimento del colesterolo, riduce l&#39;aterosclerosi in apolipoproteina E-carenti (topi apoE(-/-)). La matrice proteica ED-B fibronectina (ED-B) &egrave; sovraregolati nelle lesioni aterosclerotiche. Utilizzando un romanzo coniugato per fluorescenza vicino infrarosso (NIRF) imaging targeting ED-B, abbiamo studiato l&#39;effetto di EZE sulla formazione di lesione della placca in topi apoE(-/-). ApoE(-/-) topi ricevuto EZE (5 tazza/kg/d) o chow fino a 4, 6 e 8 mesi di et&agrave;. Imaging NIRF delle lesioni dell&#39;aorta &egrave; stata eseguita 24 ore dopo l&#39;applicazione per via endovenosa, ex vivo e in vivo. Formazione di placca lesione &egrave; stata analizzata da istologia e immunoistochimica. Formazione di lesione aortica rilevata dalla colorazione Sudan e imaging NIRF era significativamente ridotto a 6 e 8 mesi (p &lt; 001 dentellatura Zone di targa determinate da imaging NIRF significativamente correlato con la colorazione di Sudan (p &lt; 001 dentellatura Trattamento di EZE ha provocato una riduzione significativa dei macrofagi della placca e immunoreattivit&agrave; ED-B (entrambi p &lt;,05) nelle lesioni brachicefala. C&#39;era una significativa riduzione nella dimensione della placca nelle arterie anonima in 8 mesi topi trattati con EZE rispetto ai topi durante il trattamento a breve termine (p &lt;,05 dai indicando la regressione di placca EZE. Imaging NIRF mirati hanno mostrato una correlazione all&#39;estensione della lesione istologica durante l&#39;intervento terapeutico in aterosclerosi sperimentale.

Monitoraggio interventi terapeutici con l&#39;utilizzo di ezetimibe mirati imaging infrarosso vicino fluorescenza nell&#39;aterosclerosi sperimentale.

This study is the first to examine the effect of direct angiotensin II type 2 (AT(2)) receptor stimulation on postinfarct cardiac function with the use of the novel nonpeptide AT(2) receptor agonist compound 21 (C21).

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

Cette &eacute;tude est la premi&egrave;re &agrave; examiner l&#39;effet de l&#39;angiotensine directe II type 2 (stimulation des r&eacute;cepteurs AT(2)) sur la fonction cardiaque post-infarctus avec l&#39;utilisation de l&#39;agoniste des r&eacute;cepteurs non peptidiques roman AT(2) compos&eacute; de 21 (C21).

2 Stimulation des r&eacute;cepteurs de l&#39;angiotensine II type : une nouvelle option d&#39;intervention th&eacute;rapeutique avec le syst&egrave;me r&eacute;nine-angiotensine dans l&#39;infarctus du myocarde ?

Questo studio &egrave; il primo ad esaminare l&#39;effetto della diretta dell&#39;angiotensina II tipo 2 (AT(2)) stimolazione del recettore sulla funzione cardiaca postinfarct con l&#39;uso dell&#39;agonista del recettore nonpeptide romanzo AT(2) compound 21 (C21).

Angiotensina II tipo 2 la stimolazione dei recettori: un romanzo opzione terapeutica interferenze con il sistema renina-angiotensina nell&#39;infarto miocardico?

High field magnetic resonance imaging (MRI) was performed to investigate the long-term effect of ezetimibe (eze), a cholesterol resorption blocker, on atherosclerotic lesion formation in the thoracic aorta of apolipoprotein E-deficient mice (apoE ( -/- )) in comparison to wild type mice (WT). Fifteen-month-old apoE ( -/- ) (Western type diet), apoE ( -/-eze ) (Western type diet with eze) which received eze (5 mc/kg/day) continuously, and age-matched WT (normal chow) were studied using contrast-enhanced 3D turbo-spin-echo sequences (RARE factor 2) on a 7 Tesla scanner. Vessel parameters were analyzed in the aortic root (AR) and aortic arch (AA) and compared to those found in histology. Plasma cholesterol levels were reduced at 15 months by 71% (P < 0.01) in apoE ( -/-eze ) compared to apoE ( -/- ). Vessel wall thickness was increased in the AR and AA in apoE ( -/- ) by 189.1 and 147.2%, respectively compared to WT. ApoE ( -/-eze ) showed reduced wall thickness in the AR (127.4%) and AA (102.8%, both P < 0.05 vs. apoE ( -/- )). A significant increase in total aortic vessel area was determined in the AR and AA in apoE ( -/- ) by 134.7 and 118.3%, respectively, compared to WT. This effect was inhibited in apoE ( -/-eze ) (AR: 126.7%, AA: 86.4%, both P < 0.05). Histological analysis confirmed the effect of eze observed by MRI and demonstrated a significant correlation between the two techniques (P < 0.001). MRI demonstrates that ezetimibe significantly reduces atherosclerotic disease in apoE ( -/- ). MRI is therefore a useful technique to perform in vivo interventional studies in experimental atherosclerosis.

High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe.

Haut champ imagerie de r&eacute;sonance magn&eacute;tique (IRM) a &eacute;t&eacute; r&eacute;alis&eacute;e pour &eacute;tudier l&#39;effet &agrave; long terme de l&#39;&eacute;z&eacute;timibe (eze), un bloqueur de r&eacute;sorption de cholest&eacute;rol, sur la formation de l&eacute;sions ath&eacute;roscl&eacute;reuses dans l&#39;aorte thoracique de souris de E-d&eacute;ficientes de l&#39;apolipoprot&eacute;ine (apoE (- / -)) par rapport aux souris de type sauvage (WT). Quinze mois apoE (- / -) (r&eacute;gime de type occidental), apoE (-/-eze) (r&eacute;gime de type occidental avec eze) qui a re&ccedil;u d&#39;eze (5 mc/kg/jour) en permanence, et WT appari&eacute;s selon l&#39;&acirc;ge (chow normal) ont &eacute;t&eacute; &eacute;tudi&eacute;s &agrave; l&#39;aide de contraste accentu&eacute; des s&eacute;quences 3D turbo-spin-&eacute;cho (facteur rares 2) sur un scanner &agrave; 7 teslas. Param&egrave;tres du navire ont &eacute;t&eacute; analys&eacute;s dans la racine aortique (AR) et de la crosse aortique (AA) et par rapport &agrave; celles que l&#39;on trouve en histologie. Cholest&eacute;rol plasmatique ont &eacute;t&eacute; r&eacute;duites &agrave; 15 mois de 71 % (P &lt; 0,01) dans apoE (-/-eze) par rapport &agrave; l&#39;apoE (- / -). &Eacute;paisseur de paroi de navire a augment&eacute; chez les AR et les AA dans apoE (- / -) par 189.1 et 147,2 %, contre respectivement en poids ApoE (-/-eze) a montr&eacute; une &eacute;paisseur r&eacute;duite dans l&#39;AR (127,4 %) et AA (102,8 %, les deux P &lt; 0,05 vs apoE (- / -)). Une augmentation significative de la portion vasculaire aortique total a &eacute;t&eacute; d&eacute;termin&eacute;e dans les AR et AA en apoE (- / -) de 134,7 et 118,3 %, respectivement, par rapport au WT. Cet effet a &eacute;t&eacute; inhib&eacute; chez apoE (-/-eze) (AR: 126,7 %, AA: 86,4 %, les deux P &lt; 0,05). L&#39;analyse histologique a confirm&eacute; l&#39;effet d&#39;eze observ&eacute;e par IRM et a d&eacute;montr&eacute; une corr&eacute;lation significative entre les deux techniques (P &lt; 0,001). MRI montre qu&#39;ezetimibe r&eacute;duit consid&eacute;rablement la maladie ath&eacute;roscl&eacute;reuse dans apoE (- / -). L&#39;IRM est donc une technique utile pour effectuer des &eacute;tudes interventionnelles in vivo dans l&#39;ath&eacute;roscl&eacute;rose exp&eacute;rimentale.

R&eacute;sonance magn&eacute;tique de haute r&eacute;solution en ath&eacute;roscl&eacute;rose souris trait&eacute;es avec l&#39;&eacute;z&eacute;timibe.

Campo ad alta risonanza magnetica (MRI) &egrave; stata eseguita per indagare l&#39;effetto a lungo termine di ezetimibe (eze), un bloccante di riassorbimento del colesterolo, sulla formazione della lesione aterosclerotica nell&#39;aorta toracica di topi E deficit di apolipoproteina (apoE (- / -)) rispetto ai topi wild type (WT). Quindici-mese-vecchio apoE (- / -) (dieta di tipo occidentale), apoE (-/-eze) (dieta di tipo occidentale con eze) che ha ricevuto eze (5 mc/kg/giorno) continuamente, e age-matched WT (chow normale) sono stati studiati usando contrasto-enhanced 3D turbo-spin-echo sequenze (raro fattore 2) su uno scanner 7 Tesla. Parametri navi sono stati analizzati nella radice aortica (AR) e dell&#39;arco aortico (AA) e rispetto a quelli trovati in istologia. Livelli plasmatici di colesterolo sono stati ridotti a 15 mesi dal 71% (P &lt; 0.01) in apoE (-/-eze) rispetto alla apoE (- / -). Lo spessore di parete del vaso &egrave; stato aumentato in AR e AA in apoE (- / -) 189,1 e 147,2% rispettivamente rispetto al WT ApoE (-/-eze) ha mostrato di spessore ridotto in AR (127.4%) e AA (102,8%, entrambi P &lt; 0.05 vs apoE (- / -)). Un aumento significativo nell&#39;area totale vaso aortico &egrave; stato determinato in AR e AA apoE (- / -) di 134,7 e 118.3%, rispettivamente, rispetto al WT. Questo effetto &egrave; stato inibito in apoE (-/-eze) (AR: 126,7%, AA: 86,4%, entrambi P &lt; 0,05). L&#39;analisi istologica ha confermato l&#39;effetto di eze osservato da MRI e ha dimostrato una significativa correlazione tra le due tecniche (P &lt; 0.001). MRI dimostra che ezetimibe riduce significativamente la malattia aterosclerotica in apoE (- / -). MRI &egrave; quindi una tecnica utile per eseguire studi interventistici in vivo nell&#39;aterosclerosi sperimentale.

Imaging a risonanza magnetica ad alta risoluzione in aterosclerotici topi trattati con ezetimibe.

Aortic stiffness, impaired fasting glucose, and aging.

Rigidit&eacute; aortique, impaired glucose &agrave; jeun et le vieillissement.

Rigidit&agrave; aortica, ha alterato il glucosio a digiuno e l&#39;invecchiamento.

To develop a single magnetic resonance (MR) imaging approach for comprehensive assessment of cardiac function and tissue properties in small animals with high heart rates.

Small animal Look-Locker inversion recovery (SALLI) for simultaneous generation of cardiac T1 maps and cine and inversion recovery-prepared images at high heart rates: initial experience.

D&eacute;velopper une seule imagerie par r&eacute;sonance magn&eacute;tique (M) approche pour l&#39;&eacute;valuation compl&egrave;te des propri&eacute;t&eacute;s de fonction et de tissus cardiaques chez de petits animaux avec des taux &eacute;lev&eacute;s de c&oelig;ur.

Petit animaux Look-Locker inversion recovery (SALLI) pour la production simultan&eacute;e de cardiaques cartes T1 et cine et inversion pr&eacute;par&eacute;s &agrave; la r&eacute;cup&eacute;ration des images &agrave; des taux &eacute;lev&eacute;s de coeur : premi&egrave;re exp&eacute;rience.

Sviluppare una singola imaging a risonanza magnetica (MR) approccio per la valutazione globale delle propriet&agrave; di funzione e il tessuto cardiaco in piccoli animali con alti tassi di cuore.

Piccolo animale Look-Locker inversione recupero (SALLI) per la generazione simultanea di cardiaci T1 mappe e immagini cine e inversione recupero-preparati a elevati tassi di cuore: iniziale esperienza.

The concentration of gadopentetate dimeglumine in myocardium and blood can be assessed from T1 measurements and can be used to calculate the extracellular volume (ECV) of the myocardium. We hypothesized that diffuse myocardial fibrosis in a small-animal model could be quantitatively assessed by measuring myocardial ECV using small-animal Look-Locker inversion recovery T1 mapping.

Assessment of diffuse myocardial fibrosis in rats using small-animal Look-Locker inversion recovery T1 mapping.

La concentration de gadopent&eacute;tate de dim&eacute;glumine dans le myocarde et le sang peut &ecirc;tre &eacute;valu&eacute;e &agrave; partir des mesures de T1 et peut &ecirc;tre utilis&eacute;e pour calculer le volume extracellulaire (AVA) du myocarde. Nous avons &eacute;mis l&#39;hypoth&egrave;se que diffuse la fibrose myocardique dans un mod&egrave;le de petits animaux pouvait &ecirc;tre &eacute;valu&eacute;e quantitativement en mesurant la VME myocardique &agrave; l&#39;aide de petits animaux Look-Locker inversion r&eacute;cup&eacute;ration T1 cartographie.

&Eacute;valuation de la fibrose myocardique diffuse chez les rats &agrave; l&#39;aide de petits animaux Look-Locker inversion r&eacute;cup&eacute;ration T1 cartographie.

La concentrazione di gadopentetate dimeglumine nel miocardio e nel sangue pu&ograve; essere valutata da T1 misure e pu&ograve; essere utilizzata per calcolare il volume extracellulare (ECV) del miocardio. Abbiamo ipotizzato che diffusa fibrosi miocardica in un modello animale di piccola potrebbe essere valutata quantitativamente misurando miocardica ECV utilizzando piccoli animali Look-Locker inversione recupero T1 mapping.

Valutazione della fibrosi miocardica diffusa nei ratti utilizzando piccoli animali Look-Locker inversione recupero T1 mapping.

Recent studies indicate that regulatory T cells (Tregs) attenuate murine atherosclerosis. Since interleukin (IL)-2 induces Tregs proliferation, we tested the impact of L19-IL2, a fusion antibody specific to extra-domain B of fibronectin (ED-B) containing an active human IL-2 molecule, in experimental atherosclerosis.

Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells.

Des &eacute;tudes r&eacute;centes indiquent que les lymphocytes T r&eacute;gulateurs (Tregs) att&eacute;nuent l&#39;ath&eacute;roscl&eacute;rose murine. &Eacute;tant donn&eacute; que l&#39;interleukine (IL) -2 induit la prolif&eacute;ration Tregs, nous avons test&eacute; l&#39;impact de L19-IL2, un anticorps de fusion sp&eacute;cifique B extra-domaine de la fibronectine (ED-B) contenant une mol&eacute;cule active de la IL-2 humaine, dans l&#39;ath&eacute;roscl&eacute;rose exp&eacute;rimentale.

Remise locale d&#39;il-2 r&eacute;duit l&#39;ath&eacute;roscl&eacute;rose par l&#39;expansion des cellules T r&eacute;gulatrices.

Studi recenti indicano che le cellule T regolatorie (Tregs) attenuano l&#39;aterosclerosi murina. Poich&eacute; l&#39;interleuchina (IL) -2 induce proliferazione Tregs, abbiamo testato l&#39;impatto di L19-IL2, un anticorpo di fusione specifico a B extra-dominio della fibronectina (ED B) contenente un&#39;umana IL-2 molecola attiva, nell&#39;aterosclerosi sperimentale.

Thore Dietrich

Internal Medicine - Cardiology

German Heart Institute Berlin

Assessment of Cardiac Function and Myocardial Morphology Using Small Animal Look-locker Inversion Recovery (SALLI) MRI in Rats

Thore Dietrich

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Internal Medicine - Cardiology

German Heart Institute Berlin

Assessment of Cardiac Function and Myocardial Morphology Using Small Animal Look-locker Inversion Recovery (SALLI) MRI in Rats

Internal Medicine - Cardiology